Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease (AADC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01973543

Recruitment Status : Completed

First Posted : October 31, 2013

Last Update Posted : March 3, 2020

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

University of California, San Francisco

Veristat, Inc.

Feinstein Institute for Medical Research

Oregon Health and Science University

Voyager Therapeutics

Information provided by (Responsible Party):

Neurocrine Biosciences

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	January 24, 2020
Actual Study Completion Date :	January 24, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Christine CW, Richardson RM, Van Laar AD, Thompson ME, Fine EM, Khwaja OS, Li C, Liang GS, Meier A, Roberts EW, Pfau ML, Rodman JR, Bankiewicz KS, Larson PS. Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2022 Jan 4;98(1):e40-e50. doi: 10.1212/WNL.0000000000012952. Epub 2021 Oct 14.

Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP, Boot B, Martin AJ, Nutt J, Thompson ME, Larson PS. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol. 2019 May;85(5):704-714. doi: 10.1002/ana.25450. Epub 2019 Mar 26.

To Top